Criteria
| Eligible Active Ingredient: | Fluticasone Furoate. As an intranasal spray not exceeding 27.5 mcg/actuation |
| With Effective From: | 1-Jun-17 |
| Indication Permitted: | Prevention and treatment of allergic rhinitis |
| Maximum Daily Dose: | 110 mcg |
| Maximum Supply per Transaction: | 3 months |
| Minimum Age of User: | 18 years |
| Patient Information Leaflet from HSA/PSS: | Download PIL (Link to HSA website) |
Mechanism of Action of Fluticasone Furoate
Fluticasone furoate is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity. The precise mechanism through which fluticasone furoate affects rhinitis symptoms is not known. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Specific effects of fluticasone furoate demonstrated in in vitro and in vivo models included activation of the glucocorticoid response element, inhibition of pro-inflammatory transcription factors such as NFkB, and inhibition of antigen-induced lung eosinophilia in sensitized rats. Fluticasone is also found to increase airway retention of long-acting beta adrenergic agonist, thus potentiating its beneficial effects for the treatment of asthma.
Additional Information of Fluticasone Furoate
| Pharmacology Class: | Decongestants And Other Nasal Preparations For Topical Use |
| Therapeutic Class: | Nasal Preparations |
| Chemical Class: | Corticosteroids |
| Synonyms: | Fluticasonum furoas | Furoate de fluticasone | Furoato de fluticasona |
Show All HSA-registered therapeutic products granted exemption to supply without prescription
References
HSA-Registered Products Containing Fluticasone Furoate As an intranasal spray not exceeding 27.5 mcg/actuation
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.